A Study of Anti-HIV Monoclonal Antibody KD-247
Public ClinicalTrials.gov record NCT00917813. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study of the Safety, Tolerability, and Pharmacokinetics of KD-247, a Humanized Monoclonal Antibody That Recognizes the Principal Neutralizing Determinant of HIV-1, in Asymptomatic HIV-1 Seropositive Individuals Who Are Not Receiving Concurrent Antiretroviral Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and tolerability of 3 infusions of KD-247 over 2 weeks in HIV-1 seropositive individuals; to determine the pharmacokinetic parameters of KD-247 when administered as above; and to assess the effect of KD-247 infusions on plasma HIV-1 ribonucleic acid (RNA) load and on CD4+ T cell counts.
Study identification
- NCT ID
- NCT00917813
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2007
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Nov 18, 2012
Started 2007
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pacific Oaks Medical Group | Beverly Hills | California | 90211 | — |
| Providence Clinical Research | Burbank | California | 91505 | — |
| Peter J. Ruane, MD, Inc. | Los Angeles | California | 90036 | — |
| Washington Hospital Center CAR | Washington D.C. | District of Columbia | 20010 | — |
| Gary Richmond, MD, PA | Fort Lauderdale | Florida | 33316 | — |
| Orlando Immunology Center | Orlando | Florida | 32803-1851 | — |
| Vita Research Solutions, Inc. | Tamarac | Florida | 33319 | — |
| AIDS Research Consortium of Atlanta | Atlanta | Georgia | 30308 | — |
| Northstar Medical | Chicago | Illinois | 60657 | — |
| Institute of Human Virology, University of Maryland | Baltimore | Maryland | 21201 | — |
| Albany Medical Center | Albany | New York | 12208 | — |
| Aaron Diamond AIDS Research Center (ADARC) | New York | New York | 10016 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| Therapeutic Concepts, P.A. | Houston | Texas | 77004 | — |
| DCOL Center for Clinical Research | Longview | Texas | 75605 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00917813, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 18, 2012 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00917813 live on ClinicalTrials.gov.